China’s First Weight-Loss Pill
According to China’s drug regulator on Thursday, orforglipron, sold in the United States as Foundayo, can be used for chronic weight management in obese or overweight adults alongside dietary changes and increased physical activity. According to the Global Times, it is classified as a Class 1 innovative drug and carries its own brand name in China.
GLP-1 drugs are synthetic versions of the naturally occurring hormone GLP-1, which regulates appetite and blood sugar, and in recent years they have become some of the world’s bestselling medicines. Orforglipron is a small-molecule, non-peptide drug taken as a daily pill without food or water restrictions, unlike some other oral GLP-1 drugs.
Its indication for type 2 diabetes is still under review. Pricing and commercial launch details in China have not yet been announced.
The Race With Novo Nordisk
The approval gives Eli Lilly an edge over Novo Nordisk in the world’s second-largest drug market. Notable developments include:
- Lilly filed its marketing application in China at the end of 2025, ahead of its rival.
- Novo Nordisk won approval for injectable Wegovy in China in 2024, but its oral version, submitted in August this year, has not yet been cleared.















